Drug developer Pfizer Inc. announced on Tuesday that they have tide up with a five year deal with Bausch & Lomb- to co-promote prescription eye-care drugs in the United States of America.
Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalmology to support patients who are at risk of blindness or suffering from vision impairment, and to serve the health care professionals who treat them.
Bausch & Lomb is one of the best-known and most respected healthcare brands in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals.
Financial terms of the five-year deal were not disclosed. The partnership includes :-
Pfizer's Xalatan® (latanoprost ophthalmic solution)
and Bausch & Lomb’s Alrex® (loteprednol etabonate ophthalmic suspension 0.2%),
Lotemax® (loteprednol etabonate ophthalmic suspension 0.5%)
and Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension).
The co-promotion agreement also will apply to Bausch & Lomb’s investigational anti-infective eye drop, besifloxacin ophthalmic suspension, 0.6%, which is currently under review by the U.S. Food and Drug Administration (FDA).
Meanwhile, Pfizer said it will continue to maintain their three mid stage developing eye-care products separate from the partnership.
The eye-care announcement follows New York-based Pfizer's move to begin selling dozens more generic drugs in the U.S. and Europe through new deals with Indian generic company Aurobindo Pharma Ltd.
We are really looking forward to experience the synergistic effects which are highly expected from the combine efforts of the two top listed eye care specialists. But if others agree with me what I feel like that along with the rising curve of Pfizer shares, a steady declining curve of world wide blindness is also expected, however, best wishes for all.
Filed under Eye Care Products, Eye Treatment | Tags: Aurobindo Pharma Ltd., Bausch & Lomb, eye, eye care, generic drugs, ophthalmic solution, ophthalmic suspension, Ophthalmology, Pfizer Inc., vision impairment | Comment Below